Emory is full of fledgling biomedical proto-companies. Some of them are actual corporations with employees, while others are ideas that need a push to get them to that point. Along with the companies highlighted by the Emory Biotech Consulting Club, Dean Sukhatme’s recent announcement of five I3 Venture research awards gives more examples of early stage research projects with commercial potential.
This is the third round of the I3 awards; the first two were Wow! Read more
Sleeping too little or too much increases the risk of cardiovascular events and death in those with coronary artery disease, according to a new paper from Emory Clinical Cardiovascular Research Institute.
Others have observed a similar U-shaped risk curve in the general population, with respect to sleep duration. The new study, published in American Journal of Cardiology, extends the finding to people who were being evaluated for coronary artery disease.
Arshed Quyyumi, MD and colleagues analyzed Read more
Vinod Thourani, associate professor of cardiac surgery at Emory School of Medicine, along with Jorge Jimenez and Ajit Yoganathan, biomedical engineers at Georgia Tech and Emory, have been teaming up to invent new devices for making heart valve repair easier.
The technology simplifies and standardizes a technique for accessing the heart via the apex, the tip of the heart’s cone pointing down and to the left. This allows a surgeon to enter the heart, deliver devices such as heart valves or left ventricular assist devices, and get out again, all without loss of blood or sutures.
Schematic of transapical aortic valve implantation. The prosthesis is implanted within the native annulus by balloon inflation.
At the conference, Thourani recalled that the idea for the device came when he described a particularly difficult surgical case to Jimenez.Â Thourani said that a principal motivation for the device came for the need to prevent bleeding after the valve repair procedure is completed.
With research and development support from the Coulter Foundation Translational Research Program and the Georgia Research Alliance VentureLab program, the company has already completed a series of pre-clinical studies to test the functionality of their device and its biocompatibility.
Researchers, physicians, and health care providers from across the United States and Italy met recently at the Rollins School of Public Health for the first Emory Conference on Mediterranean Diet and Health. Participants focused on the diet’s relation to cardiovascular disease, cancer, neuropsychiatric disorders, and vascular health.
The Mediterranean diet is characterized by a high consumption of fruits, vegetables, legumes, complex carbohydrates, and nuts; moderate consumption of fish and red wine; low consumption of cheese and red meat; and olive oil as the chief source of fat, explains Viola Vaccarino, MD, PhD, one of the conference chairs.
When topped with exercise, the Mediterranean dietâ€”really a pattern of eating habits traditionally followed by people in the Mediterranean regions in the early 1960sâ€”has proven beneficial for many throughout the years. But why this is so isnâ€™t clear. Read more
Itâ€™s not a silly question, when one sees how oxidative stress and reactive oxygen species have been implicated in so many diseases, ranging from hypertension and atherosclerosis to neurodegenerative disorders. Yet large-scale clinical trials supplementing participantsâ€™ diets with antioxidants have showed little benefit.
Emory University School of Medicine scientists have arrived at an essential insight: the cell isnâ€™t a tiny bucket with all the constituent chemicals sloshing around. To modulate reactive oxygen species effectively, an antioxidant needs to be targeted to the right place in the cell.
Sergei Dikalov and colleagues in the Division of Cardiology have a paper in the July 9 issue ofÂ Circulation Research, describing how targeting antioxidant molecules to mitochondria dramatically increases their effectiveness in tamping down hypertension.
Mitochondria are usually described as miniature power plants, but in the cells that line blood vessels, they have the potential to act as amplifiers. The authors describe a â€œvicious cycleâ€ of feedback between the cellular enzyme NADPH oxidase, which produces the reactive form of oxygen called superoxide, and the mitochondria, which can also make superoxide as a byproduct of their energy-producing function.
Peripheral artery disease affects millions of people in the United States. It’s basically hardening of the arteries (atherosclerosis) leading to problems with getting enough blood to the limbs. Symptoms of severe PAD include leg pain that doesn’t go away once exertion stops and wounds that heal slowly or not at all.
Lifestyle changes, medication and surgery can address some cases of PAD, but often the disease is not recognized until it has advanced considerably. At Emory, cardiologist Arshed Quyyumi has been exploring whether a patient’s own bone marrow cells can repair the arteries in his or her limbs.
There have been tremendous advances in cardiac surgery over the years. Physicians can now operate on children with heart defects in the first month or week of their lives. But very little is known about how the human heart develops especially in that first year after birth.
Emory and Childrenâ€™s Healthcare of Atlanta researcher Mary Wagner, PhD, is leading a project looking at how the heart develops during the first year of life. This is critical, she says, because childrenâ€™s hearts respond differently to medications and surgery than adultsâ€™ hearts, and many treatments currently available to pediatric heart patients were designed and tailored specifically for the adult heart.
Wagner, associate professor in Emory’s School of Medicine, and her research team will examine the physiological properties of human heart tissue from pediatric patients. The samples are tissue that needs to be removed as part of the surgical repair of the patientâ€™s heart and would otherwise be discarded.
The ultimate goal of Wagnerâ€™s research is to examine the differences in the human heart in the first year after birth and identify novel target therapies for the pediatric cardiac patient.
Wagnerâ€™s research labs are housed at The Emory-Childrenâ€™s Center, a joint venture between Emory Healthcare and Childrenâ€™s Healthcare of Atlanta.
An aging U.S. population, an increase in the prevalence of obesity and improved cardiovascular therapies for acute problems are boosting the number of people living with the condition of heart failure.
Javed Butler, MD, MPH, director of heart failure research at Emory Healthcare and associate professor of medicine at Emory University School of Medicine, is looking for new ways to prevent and treat heart failure.
According to Butler, heart failure is any condition in which the heart is unable to pump enough blood for the metabolic needs of the body, but that does not mean that the heart is not cheap oakleys pumping or the heart has stopped working. Heart failure is not a disease but a syndrome, so thereâ€™s a whole family of different diseases that can precede this condition. These are known collectively as heart failure.
In the clinic, Butler treats patients already diagnosed with heart failure. His research focuses on prevention through life style changes as well as models pinpointing who is at risk for heart failure.
Butler and his colleagues recently created the Health ABC Heart Failure Model for predicting risk of new onset heart failure in the elderly. That model has now been strengthened by validating it via a library of patient data from an earlier cardiovascular study. The results suggest the Health ABC risk model can be used to identify high-risk individuals for whom interventions can be cost-effectively targeted to prevent heart failure.
To hear Butlerâ€™s own discussion about heart failure, access the podcast from Emoryâ€™s Sound Science series.
Abdominal aortic aneurysms (AAA) are a major cause of illness and death in the U.S., with the incidence increasing dramatically over the age of 55. These aneurysms are a widening and bulging of the large artery that runs through the body from the heart into the abdomen. They often go undetected until they suddenly rupture, often resulting in death within minutes.
A team of physicians and engineers from Emory and Georgia Tech is studying the biology and biomechanics of vascular inflammation and disturbed blood flow in AAAs to understand how they develop and could be prevented or detected earlier.
Taylor points out that predicting the likelihood of aneurysm rupture is extremely difficult and patients often donâ€™t notice them until they already are leaking or ruptured. Even small aneurysms often expand rapidly and rupture. He and his team will try to pin down specific risk factors for AAAs, which they think differ from traditional cardiovascular risk factors.